News

Wyeth Pharmaceuticals, a division of Wyeth, has submitted a biologic license application to the FDA for Prevnar 13, pneumococcal 13-valent conjugate vaccine. The Prevnar 13 submission to the

ReNeuron Group, a UK-based stem cell company, has reported positive preclinical efficacy data with its lead CTX stem cell line in a model of peripheral arterial disease, a

Vasomedical, a manufacturer of enhanced external counterpulsation therapy systems, has received the FDA 510(k) clearance to market Vasomedical-Biox 1305 ECG Holter monitor and CB series ambulatory ECG analysis

GlaxoSmithKline has submitted two simultaneous regulatory applications to expand the use of Tyverb/Tykerb. If approved, Tyverb/Tykerb could be used as a first-line therapy regimen combined with anti-hormonal therapy

OXiGENE has initiated a Phase Ib/IIa study of its dual-mechanism, second-generation vascular disrupting agent, OXi4503, in patients with solid tumors with hepatic involvement. The multi-center study is being

XTL Biopharmaceuticals has reported a net loss of $9.25m, or $0.03 per ordinary share, for the year ended December 31, 2008, compared to a net loss of $24.94m,

Mr McCutcheon joins Ventus Medical from Emphasys Medical where he was president and CEO for the past seven years. Previously, Mr McCutcheon was head of sales and marketing

Celsion, a biotechnology company, has reported promising clinical results from its Phase I trial evaluating ThermoDox for the treatment of recurrent chest wall breast cancer. The Phase I

Orthocon’s $25 million financing was co-led by ProQuest Investments and Canaan Partners. The round has also included significant participation from Orthocon’s existing stockholder BB Biotech Ventures. Joyce Tsang,